SOAT1 and COVID-19: Baricitinib, initially approved for the treatment of rheumatic arthritis [44], is now employed for the treatment of hospitalized patients with severe COVID-19 [45], since one of the molecular mechanisms central to the development of the cytokine storm in COVID-19 is the JAK/STAT pathway [46,47].